International Stem Cell (ISCO) Other Operating Expenses (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Other Operating Expenses of $911000.0 for Q4 2025, down 24.08% year-over-year from $1.2 million in Q4 2024, and down 24.46% quarter-over-quarter from $1.2 million in Q3 2025.
International Stem Cell (ISCO) Other Operating Expenses (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Other Operating Expenses for 16 consecutive years, with $911000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Operating Expenses fell 24.08% year-over-year to $911000.0; the TTM figure through Dec 2025 stood at $4.6 million (down 3.16% YoY), while the FY2025 annual figure was $4.7 million, up 6.7% from the prior year.
- Other Operating Expenses eased to $911000.0 in Q4 2025 per ISCO's latest filing, from $1.2 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $1.4 million in Q4 2022 and bottomed at $758000.0 in Q2 2023.
- Historically, Other Operating Expenses has averaged $1.1 million across 5 years, with a median of $1.1 million in 2022.
- Annual changes were most pronounced in 2021 — Other Operating Expenses slipped 29.99% — and 2024, when it soared 60.29%.
- International Stem Cell's Other Operating Expenses stood at $938000.0 in 2021, then jumped by 49.15% to $1.4 million in 2022, then fell by 15.44% to $1.2 million in 2023, then gained by 1.44% to $1.2 million in 2024, then declined by 24.08% to $911000.0 in 2025.
- Business Quant data shows ISCO's Other Operating Expenses at $911000.0 in Q4 2025, $1.2 million in Q3 2025, and $1.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.37 Mn |
| Dec 31, 2025 | 911,000.00 |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.27 Mn |
| Jun 30, 2024 | 1.22 Mn |
| Mar 31, 2024 | 1.06 Mn |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | 936,000.00 |
| Jun 30, 2023 | 758,000.00 |
| Mar 31, 2023 | 969,000.00 |
| Dec 31, 2022 | 1.40 Mn |
| Sep 30, 2022 | 1.05 Mn |
| Jun 30, 2022 | 1.04 Mn |
| Mar 31, 2022 | 1.03 Mn |
| Dec 31, 2021 | 938,000.00 |
| Sep 30, 2021 | 1.17 Mn |
| Jun 30, 2021 | 883,000.00 |